Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Gene therapy and special goggles help some blind adults detect objects again (opens in a new tab)

news-medical.net · 2026-10-12

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 7Not checkedA recent New England Journal of Medicine study evaluated the safety and preliminary visual-function outcomes of optogenetic therapy in adults with advanced retinitis pigmentosa.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 7Not checkedThe current phase 1, multicenter, open-label, nonrandomized PIONEER study evaluated GS030, consisting of an intravitreal optogenetic vector and light-stimulating goggles, in adults with advanced retinitis pigmentosa.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 7Not checkedTen participants were enrolled in three sequential dose groups, each receiving a single injection in the worse-seeing eye; the main outcome was safety, including adverse events, intraocular pressure, retinal imaging, and immune responses.View evidenceHide evidence

As stated10 participants; 3 dose groups

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 7Not checkedThe treatment was generally tolerated, with mostly mild or moderate ocular adverse events and one transient severe central retinal artery occlusion immediately after injection.View evidenceHide evidence

As stated1 severe transient ocular event

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 7Not checkedAfter treatment, light sensitivity improved in seven participants during testing with the goggles, and six achieved clinically meaningful gains.View evidenceHide evidence

As stated7 participants; 6 clinically meaningful gains

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 6 of 7Not checkedFour of eight participants who completed visual behavioral testing were considered responders because they showed modest gains in object detection or discrimination when using the goggles.View evidenceHide evidence

As stated4 of 8 responders

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 7 of 7Not checkedThe article says these improvements did not restore detailed or color vision, and larger controlled studies are needed to establish efficacy and longer-term safety.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Optogenetic Therapy for Restoring Aspects of Visual Function

New England Journal of Medicine · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

55. Preclinical Safety Studies for AAV2-MerTK Gene Therapy Vector for Retinitis Pigmentosa

Molecular Therapy · 2013 · Crossref

Source (opens in a new tab)
Candidate

Correction to: Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors

Human Molecular Genetics · 2024 · Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

And 10 more candidates considered.